Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.73 |
| ▸ | CTSS | P25774 | 4/20 | 0.73 |
| ▸ | CTSL | P07711 | 3/20 | 0.73 |
| ▸ | CTSB | P07858 | 1/20 | 0.73 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.64 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5934709 | 0.98 | CTSK (0.76) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL5934832 | 0.93 | CTSK (0.70) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL5934902 | 0.93 | CTSK (0.70) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL7165207 | 0.91 | CTSK (0.70) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL5935127 | 0.91 | CTSK (0.77) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL7411658 | 0.90 | CTSK (0.76) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL7402633 | 0.90 | CTSK (0.76) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL11361534 | 0.90 | CTSK (0.76) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL5934889 | 0.90 | CTSK (0.66) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL27562904 | 0.90 | CTSK (0.69) | CTSKCTSSCTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12050219-B2 | Modulating biomarkers such as SPP to increase tumor immunity and improve the efficacy of cancer immunotherapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20220057403-A1 | MODULATING BIOMARKERS SUCH AS SPP TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY | DANA-FARBER CANCER INSTITUTE, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20080213172-A1 | RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213172-A1 | RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES | LAP3, DNPEP, ACE | CTSK 219/4885CTSS 102/4885CTSL 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.